ERBB2 and breast cancer: In this cohort study of 79 breast cancer patients, we investigated the stability and changes of key IHC biomarkers (ER, PR, HER2, Ki-67) from the time of initial diagnosis (biopsy) to definitive surgery, in relation to patient age, tumor grade, molecular subtype, and treatment.